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Summary
We have previously reported that plasma fibrin D-dimer (a marker
of turnover of cross-linked fibrin) showed a strong and independent as-
sociation with incident ischaemic heart disease (IHD) in the Caerphilly
Study cohort of 1,998 men aged 49-65. To establish the specificity of
this finding, we assayed plasma samples from this cohort with a more
specific assay for fibrin D-dimer: this showed an association with inci-
dent IHD which was at least as strong and independent as that for the
original assay (odds ratio, OR for top fifth compared to bottom fifth
3.79; 95% CI 1.77-8.10; p < 0.0001). To establish potential causes of
the increased fibrin turnover, we also assayed several potential markers
of coagulation activation or thrombotic tendency (prothrombin frag-
ment F1+2, thrombin-antithrombin complexes, factor VIIc, activated
partial thromboplastin time [APTT] and activated protein C resistance):
none of these variables were associated with incident IHD in this 
cohort.  We suggest that further studies are required to establish the
causes of increased cross-linked fibrin turnover, which is associated
with incident IHD in the general population when measured by a 
specific assay.
Introduction
We have recently reported that plasma fibrin D-dimer, a marker of
the formation and lysis of cross-linked fibrin (1, 2), showed a strong
and independent association with incident ischaemic heart disease
(IHD) in the Caerphilly Study (3). This finding, which is consistent
with results from several other studies (4), was not explained by asso-
ciations of IHD with plasma fibrinogen (the precursor of fibrin), nor
with plasma levels of tissue plasminogen activator (t-PA) antigen or
plasminogen activator inhibitor (PAI) activity, which play key roles in
the lysis of fibrin (3). We suggested that increased plasma D-dimer 
levels in men at increased risk of IHD might reflect increased activa-
tion of blood coagulation, because similar elevations of coagulation 
activation markers and D-dimer have been observed in case-control 
studies of patients with chronic arterial disease (4-6), and because in-
creased plasma D-dimer levels can be normalised by anticoagulation
with warfarin to conventional target INR levels (7, 8).
We have performed further investigations in stored, unthawed, deep-
frozen plasma samples from this study cohort, to investigate possible
causes of the association of fibrin D-dimer with incident IHD. First, we
addressed the problem of heterogeneity of D-dimer assays (9) by inve-
stigating whether or not the association of D-dimer with incident IHD
could be confirmed using a more specific assay which employs a more
specific signal antibody (10). Second, we studied the association of 
several assays of coagulation activation or thrombotic tendency with 
incident IHD and with D-dimer levels: prothrombin fragment F1+2 and
thrombin-antithrombin complexes (11, 12), factor VIIc (13), activated
partial thromboplastin time (APTT), and activated protein C (APC) 
resistance using a modification of the original assay of Dählback et al.
(14) which we have previously associated with increased levels of 
coagulation activation markers in another population study (15). We
are unaware of reported studies of the correlations between D-dimer
and markers of activated coagulation in large samples of the general 
population.
Subjects and Methods
The general design and methods of the Caerphilly Study have been descri-
bed elsewhere (3). Briefly, at each examination the men were invited to attend
an afternoon or evening clinic where a detailed medical and lifestyle history
was obtained, the London School of Hygiene and Tropical Medicine (LSHTM)
chest pain questionnaire was administered, a full 12 lead electrocardiogram
(ECG) was recorded, and weight and blood pressure measured. The men were
then invited to return, fasting, to an early morning clinic where a blood sample
was taken.
Study Population
The original cohort of 2,512 men aged 45 to 59 years was recruited between
1979 and 1983, and since then they have been re-examined at five yearly inter-
vals. The men who are the subject of this report are those seen at the first re-ex-
amination between 1984 and 1988, when they were aged 49 to 65 years. Men of
the same age who had moved into the defined geographical area since the 
original recruitment were also eligible to be examined. A total of 2,398 men 
attended the evening clinic and a fasting blood sample was obtained from 2,223
(93%).
Correspondence to: Prof. G. D. O. Lowe, University Department of 
Medicine, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow, G31
2ER; UK – Tel: +44 141 211 5412; Fax: +44 141 211 0414; E-mail:
gdl1j@clinmed.gla.ac.uk
Fibrin D-dimer, Markers of Coagulation Activation and the Risk
of Major Ischaemic Heart Disease in the Caerphilly Study
Gordon D. O. Lowe1, Ann Rumley1, Peter M. Sweetnam2, John W. G. Yarnell 3, 
Joseph Rumley1
1University Department of Medicine, Royal Infirmary, Glasgow, the 2MRC Epidemiology Unit (South Wales), 
Llandough Hospital, Penarth, and 3 Division of Epidemiology, Queen’s University, Belfast, UK
823
Lowe et al.: Coagulation Activation and Ischaemic Heart Disease
Blood Collection, Storage and Analysis
Blood was taken between 7.00 am and 10.00 am for 91% of the men. It was
taken before 7.00 am for 7% and between 10.00 am and 11.00 am for the 
remaining 2%. The blood was collected without venous stasis into evacuated
containers using a 19-gauge butterfly needle and Sarstedt monovette adaptors.
Centrifugation was carried out within one hour. The samples used in this study
were citrated plasma stored at -70° C.
One batch of samples was unavailable for the current analysis, so assays of
fibrin D-dimer were performed on 1,998 fasting samples. For comparison with
the D-dimer ELISA originally used (Dimertest ELISA, AGEN, Parsippany,
New Jersey, USA), D-dimer was re-assayed on 1947 samples using the more
specific assay (10) (AGEN Gold, AGEN, Parsippany, New Jersey, USA). The
other assays were measured on a separate plasma sample, about one-third of
which had previously been used for another purpose. Hence, 1,412 samples 
were available for assay of Factor VIIc (automated one-stage assay, ACL 300
Research coagulometer, Instrumentation Laboratory, Warrington, UK) using
the manufacturer’s reagents and British Standard (NIBSC, South Mimms,
Herts, UK). In the majority of these samples (n = 1325-1360) sufficient residu-
al plasma was available for assays of APTT and APC ratio (ACL 300 Research
coagulometer) using Coatest APC-resistance kits (Chromogenix, Stockholm,
Sweden) based on the original assay of Dahlbäck et al. (14,15); and prothrom-
bin fragment F1+2 and thrombin-antithrombin (TAT) complexes (ELISA’s,
Behringwerke, Marburg, Germany) using an automated microtitre plate reader
(Dynatec, Billingshurst, UK). The characteristics of this subsample were very
similar to those of the whole sample. Fibrinogen (Clauss assay) and factor VIIIc
were also assayed in this subsample: their associations with IHD (as well as
those for von Willebrand factor antigen and activity) in this cohort are reported
elsewhere (16, 17).
Incident IHD
Follow-up was at an average interval of 61 months. All men were flagged
with the National Health Service Central Registry and we used death certifi-
cates coded to ICD 410-414 inclusive as our definition of fatal IHD. We added
to the LSHTM questionnaire some questions about admission to hospital with
chest pain. These, together with lists from Hospital Activity Analysis of all men
admitted to local hospitals with a diagnosis of ICD 410-414, were used as the
basis for a search of hospital notes for events meeting standard World Health
Organisation (1996) criteria for acute myocardial infarction (MI). Finally, the
appearance on the follow-up electrocardiogram (ECG) of selected major or 
moderate Q-waves (Minnesota codes 1-1-1 through 1-2-5 and 1-2-7) when 
there were no Q-waves on the recruitment ECG was taken as evidence that a
non-fatal MI had occurred during the follow-up period.  
Statistical Methods
Outlying values of TAT (≥ 31 g/L) were excluded from statistical analysis
(101 out of 1334 measurements excluded). Adjusted mean differences 
(Table 4) were obtained by analysis of covariance. All variables except Factor
VIIc and APC ratio were transformed to logarithms. The remainder of the 
analysis was performed using multiple logistic regression analysis with the 
occurrence, or not, of a major incident IHD event as the dependent variable.
The results for the assays were treated in two ways. First, their distributions 
were divided into equal fifths using the four quintiles, and the results presented
as the odds of major incident IHD in each fifth relative to a baseline fifth which
was always taken as the 20% of men with the lowest levels. Second, these 
variables were entered into the same models as continuous variables to provide
a test for the trend in the relative odds of IHD. When treated as continuous 
variables all, except Factor VIIc and APC ratio, were again transformed to 
logarithms.
Men with evidence of ischaemia at recruitment were not excluded from the
analysis. Reasons for this are given elsewhere (3). Briefly, 31% of this general
population sample men have some evidence of ischaemia at baseline as judged
from the LSHTM chest pain questionnaire or the ECG. Exclusion of such a 
large group, among whom just over half the major incident events occur, does
not seem satisfactory. Instead we included standardised measures of angina, 
history of severe chest pain and ECG ischaemia at baseline as three covariates
in the logistic regression analysis. This is likely to be a conservative procedure
in that it may underestimate the association between the thrombotic factors and
incidence of IHD.
Results
Table 1 shows the joint distributions of the original D-dimer assay
and the more specific D-dimer Gold assay, based on 1,945 samples
with fasting values for both assays. There was a strong correlation bet-
ween the two assays (r = 0.59). The fifths of distributions were identi-
cal for 35% of the men, and within ± 1 fifth for 76%. Only 1.4% of the
men were in the top fifth for one antigen and in the bottom fifth for the
other.
Table 2 shows that the values of the D-dimer Gold assay were 
significantly lower than for the original D-dimer assay. However, both
assays showed a strong trend (p < 0.0001) for the incidence of IHD to
increase from about 3% in the 20% of men with the lowest levels of 
D-dimer to about 12% in the 20% of men with the highest levels. 
There was no statistically significant difference between the two assays
for these associations with incident IHD. As with the original assay (3),
controlling for baseline IHD and for conventional risk factors (age,
smoking, diastolic blood pressure, body mass index, total and HDL
cholesterol, diabetes, family history of MI before age 55, and time of
blood sample), reduced the trend for D-dimer Gold, but it remained 
highly statistically significant (p < 0.0001); and the relative odds in the
top fifth when compared to the bottom fifth were 3.79 (95% CI 
1.77-8.10). The further inclusion of fibrinogen into the model had no
effect whatsoever on this association (data not shown).
Table 1 Joint distributions of D-dimer and
D-dimer gold
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Table 2 Incidence and
age-related relative odds of
IHD over 5 years by fifths
of D-dimer and D-dimer
gold
Table 3 Correlation coef-
ficients between D-dimer
assays, fibrinogen, factor
VIIIc and coagulation ac-
tivation markers
Table 4 Mean levels (with
inter-quartile range, IQR)
and age-adjusted mean dif-
ferences (with 95% confi-
dence intervals) between
men who developed major
IHD over 5 years and those
who did not
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Table 3 shows that each assay for D-dimer correlated significantly
with plasma fibrinogen, FVIIIc, F1+2, TAT, and APC ratio (the latter
correlation being inverse); but not with APTT or FVIIc. The strength
and pattern of all these correlations was very similar for the two 
D-dimer assays. There were also significant correlations between the
other activation markers, notably FVIIIc and APTT.
Tables 4 and 5 shows that, in contrast to D-dimer, fibrinogen (16)
and FVIIIc (17), no significant associations with incident IHD were ob-
served for F1+2, TAT, FVIIc, APTT or APC ratio.
Discussion
The first aim of this study was to establish whether, in view of the
heterogeneity of D-dimer and its assays (9), the association of plasma
D-dimer with incident IHD which we have previously reported in the
Caerphilly Study cohort (3) could be validated using a more specific as-
say for D-dimer which employs a more specific signal antibody (10).
In agreement with a previous comparison (10), we observed a strong
correlation between these two assays. As expected, the more specific
assay gave lower values for plasma D-dimer than the original assay
(10); and there was also some variation between distributions by fifths
(Table 1). Nevertheless, the main finding of this comparison was that
the more specific assay showed an association with incident IHD which
was at least as strong, and as independent of other risk factors including
fibrinogen, as that which we reported (3) for the original assay (Table
2). We therefore conclude that a significant association exists between
the various plasma fibrin derivatives which contain D-dimer (9) and 
incident IHD. These findings in the present study are consistent with 
those of other prospective studies of cardiovascular events, in cohorts
both with and without evidence of baseline cardiovascular disease (4).
Recently, comparison of two different D-dimer assays showed that they
had similar associations with recurrent thrombotic events following
myocardial infarction (18,19). Together with the results of the present
study, these data support the consistency of the association of plasma
D-dimer with incident IHD, regardless of assay type. However, further
comparative studies are required.
We have suggested that increased plasma D-dimer levels in persons
developing IHD might reflect increased activation of blood coagula-
tion, because similar elevations of coagulation activation markers and
D-dimer have been observed in patients with chronic arterial disease 
(4-6), and because increased plasma D-dimer levels can be normalised
by anticoagulation with warfarin (7, 8). However, we are unaware of 
reported studies of the correlations between D-dimer and markers of 
activated coagulation in large samples of the general population. There-
fore, the second aim of this study was to examine the correlations of
both D-dimer assays with several markers of activated coagulation; and
also to examine the associations of these markers with incident IHD.
Both D-dimer assays correlated similarly with plasma fibrinogen 
(r = 0.30–0.36; Table 3), which has been associated with incident IHD
in this cohort (16). These correlations might arise from mutual correla-
tions with age, smoking and baseline arterial disease (20); from an 
influence of fibrinogen on D-dimer formation; or vice versa (e.g. from
stimulation of hepatic fibrinogen synthesis by fibrin(ogen) degradation
products including D-dimer) (4). However, inclusion of fibrinogen in
multivariate analyses had virtually no effect on the associations of 
either type of D-dimer assay with IHD, hence such associations do not
appear to result from the influence of fibrinogen levels.
Both D-dimer assays also correlated with factor VIIIc, which has al-
so been associated with incident IHD in this cohort (17). As with fibri-
nogen, these correlations might arise from mutual correlations with age
(21); from an influence of factor VIIIc on thrombin and fibrin formati-
on, and hence D-dimer formation; or from a mutual influence of throm-
bin formation on activation of FVIII and on D-dimer formation. How-
ever, this association was weak (r = 0.16-0.20).
The coagulation activation markers, F1+2 and (to a lesser extent)
TAT, also showed significant correlations with both D-dimer assays.
These correlations, which have been observed in other studies (22),
might arise from mutual correlations with age, risk factors, or baseline
arterial disease (11, 12, 21); or from an influence of thrombin forma-
tion (leading to F1+2 and TAT formation) on formation of fibrin and
hence on D-dimer. However, these activation markers were not asso-
ciated with incident IHD in this cohort, hence they do not appear to ex-
plain the association of D-dimer assays with incident IHD
Activated protein C resistance (as measured by a low APC ratio) 
also correlated with both D-dimer assays, as well as F1+2 and TAT.
These associations, which have been observed in other studies (15, 22)
Table 5 Incidence, age, adjusted relative
odds of IHD over 5 years, and t-tests for
trends by fifths of coagulation activtion 
markers
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might reflect effects of increased VIIIc levels on both coagulation 
activation (21) and on APC resistance (15, 21); or else that a low APC
ratio is associated with a hypercoagulable state (15). However, APC 
ratio was not associated with incident IHD in this study cohort, nor with
prevalent IHD in other studies (15, 23), hence again this assay does not
explain the association of D-dimer assays with incident IHD. APTT,
while associated with coagulation activation and incident DVT in other
studies (22), was associated with neither D-dimer assays nor with 
incident IHD in the present study.
We observed no correlation of FVIIc with D-dimer assays, although
several studies have correlated FVII assays with coagulation activation
markers such as fibrinopeptide A, F1+2 and TAT (12, 21). This nega-
tive finding may reflect the limited range of FVIIc in the present study,
because in contrast anticoagulation with warfarin (which lowers FVIIc)
has been shown to normalise elevated D-dimer levels in several studies
(7, 8, 24). We also observed no independent association of FVIIc with
incident IHD in this cohort, as have several other prospective studies
(25-27). The association of FVIIc with incident IHD in the first 
Northwick Park Heart Study (13) may reflect a higher sensitivity of the
FVIIc assay used in that study to FVIIa (28).
There are several limitations of the current study. First, activation
markers could only be assayed in the two-thirds of the sample for which
an unthawed plasma sample was available. We have compared this
subsample with the total sample, and confirmed that no selection bias
occurred. We also examined the association of D-dimer with IHD in the
subsample in whom activation markers were measured, and confirmed
that both D-dimer assays were significantly associated with IHD within
this subsample. Second, the short half-lives (min) of activation markers
in the circulation make it more difficult to establish an association with
incident IHD, compared to D-dimer which has a longer half-life (h).
For both these reasons, further, larger studies are required to study the
associations of activation markers with IHD. Third, the current study
included only men: a recent report (29) suggested the possibility that 
D-dimer was not of prognostic value in women compared to men (al-
though only 14 events occurred in women in this study). Hence, further
studies of the association of D-dimer with incident IHD in women are
required.
In conclusion, the present study confirms with a specific assay a
strong association of  fibrin D-dimer with incident IHD, but does not
clearly establish a role for several assays of coagulation activation or
thrombotic tendency in explaining this association (perhaps due to a 
lower study power). We suggest that further studies are required to 
investigate other potential causes of this association. These may 
include an effect of disturbed blood flow (e. g. due to atherosclerotic
plaques) on D-dimer, as seen in patients with atrial fibrillation under-
going cardioversion (30); and the possible association of fibrin turnover
with the inflammatory component of atherosclerosis (31).
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